Cancer biotech ends trial, searches for sale or other route
Aileron Therapeutics has scrapped its trial, laid off most employees and is searching for a merger partner or other strategic alternative.
The Boston biotech said a review of initial data from a Phase Ib trial showed patients “experienced severe neutropenia (Grade 4) and alopecia,” commonly known as hair loss. Aileron was testing its drug ALRN-6924 in patients with p53-mutated breast cancer. The open-label study was testing neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, also known as “TAC” chemotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.